All Videos

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis.

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

Jeanine Downie, MD, FAAD, discussed critical updates on tattoo ink safety, new dermatologic technologies, biostimulators, and more at AAD 2025.

Along with his session insights on diet and chronic spontaneous urticaria, Friedman shares tips for navigating the largest dermatology conference in the US.

Ahead of the annual meeting, Dermatology Times spoke with Draelos about why she looks forward to the meeting each year.

Adamson highlights key topics to expect at the AAD Annual Meeting, emphasizing the importance of tackling controversial issues and fostering collaboration.

Panelists discuss how the JAK-STAT signaling pathway mediates inflammatory responses in atopic dermatitis, influencing disease progression and providing a key therapeutic target for treatment.

Panelists discuss how clinicians can choose the most appropriate systemic treatment for moderate to severe atopic dermatitis by evaluating patient characteristics, comorbidities, and therapeutic goals while considering the latest clinical evidence.

Patrick Burnett, MD, PhD, shares key updates expected in 2025 for therapeutics treating atopic dermatitis, alopecia areata, and more.

The panelist discusses how to safely transition a 36-year-old man with a history of systemic corticosteroid use to appropriate oral treatment options while monitoring for potential complications.

The panelist discusses how to evaluate the need for and manage the transition between biologic therapies in a 32-year-old woman with severe atopic dermatitis who has had an inadequate response to initial treatment.

Robinson shared insights into how the company is working to fight clinical research disparities.

Dustin Portela, DO, discuss how Swift microwave therapy can enhance patient care, generate referrals, and offer a promising revenue stream, while keeping pace with ongoing advancements in the technology.

Dustin Portela, DO, highlights how the design of Swift microwave therapy improves efficiency, simplifies training for medical assistants, and enhances practice flexibility.

In this episode, Dustin Portela, DO, explores how Swift microwave therapy enhances efficiency and allows physicians to focus on other aspects of care.

Dustin Portela, DO, discusses patient selection and affordability considerations for Swift microwave therapy. He explores how the treatment process works and strategies to ensure patient comfort during sessions.

In this episode, Dustin Portela, DO, explores how Swift microwave therapy is transforming wart treatment, the science behind this technology, and how it reduces wart-related pain.

In this episode, Dustin Portela, DO, discusses how treating warts can be a challenge and explores the effectiveness of Swift microwave therapy. The episode reviews how this innovative approach compares to traditional methods and helps patients achieve lasting results.

An expert discusses how treatment for alopecia areata begins with topical/intralesional therapies for limited disease and progresses to systemic options for extensive involvement or treatment resistance. Treatment decisions are guided by disease severity, patient age, comorbidities, and treatment goals. FDA-approved systemic agents include ritlecitinib (JAK3/TEC inhibitor) and baricitinib (JAK1/2 inhibitor), which block inflammatory pathways to promote hair regrowth with favorable efficacy, though they require monitoring for potential adverse effects.

An expert discusses how alopecia areata affects approximately 2% of the population globally, with onset typically in childhood or early adulthood. Patients often present with autoimmune comorbidities (thyroid disorders, vitiligo, atopic dermatitis) and psychological distress. Diagnostic challenges include differentiating from other hair loss conditions and predicting disease course. Treatment difficulties involve unpredictable responses, lack of standardized protocols, and addressing both physical symptoms and psychological impact.

Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.

Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.

Panelists discuss how physicians can achieve optimal atopic dermatitis management by following American Academy of Dermatology (AAD) guidelines for systemic therapy selection while considering individual patient factors and treatment goals.

Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.

Independent pharmacies are closing at high rates, leaving many communities without essential health care access.

The panelist discusses how to optimize topical therapy selection and application strategies for a young man with mild atopic dermatitis to achieve symptom control and maintain skin barrier function.

The panelist discusses how to effectively communicate the benefits and potential adverse effects of dupilumab treatment to patients and their families to support informed decision-making.

Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.